- Home
- TNGX vs ITOS Comparison
TNGX vs ITOS Comparison
Compare TNGX & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ITOS
- Stock Information
- Founded
- TNGX 2014
- ITOS 2011
- Country
- TNGX United States
- ITOS United States
- Employees
- TNGX N/A
- ITOS N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNGX Health Care
- ITOS Health Care
- Exchange
- TNGX Nasdaq
- ITOS Nasdaq
- Market Cap
- TNGX 413.6M
- ITOS 342.6M
- IPO Year
- TNGX N/A
- ITOS 2020
- Fundamental
- Price
- TNGX $3.92
- ITOS $8.32
- Analyst Decision
- TNGX Strong Buy
- ITOS Strong Buy
- Analyst Count
- TNGX 8
- ITOS 3
- Target Price
- TNGX $13.14
- ITOS $33.67
- AVG Volume (30 Days)
- TNGX 3.5M
- ITOS 543.4K
- Earning Date
- TNGX 11-06-2024
- ITOS 11-12-2024
- Dividend Yield
- TNGX N/A
- ITOS N/A
- EPS Growth
- TNGX N/A
- ITOS N/A
- EPS
- TNGX N/A
- ITOS N/A
- Revenue
- TNGX $43,383,000.00
- ITOS $35,000,000.00
- Revenue This Year
- TNGX $25.55
- ITOS $271.18
- Revenue Next Year
- TNGX N/A
- ITOS N/A
- P/E Ratio
- TNGX N/A
- ITOS N/A
- Revenue Growth
- TNGX 15.67
- ITOS N/A
- 52 Week Low
- TNGX $2.70
- ITOS $7.54
- 52 Week High
- TNGX $13.01
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- TNGX 39.26
- ITOS 39.51
- Support Level
- TNGX $3.54
- ITOS $7.54
- Resistance Level
- TNGX $4.22
- ITOS $8.38
- Average True Range (ATR)
- TNGX 0.53
- ITOS 0.53
- MACD
- TNGX 0.13
- ITOS 0.01
- Stochastic Oscillator
- TNGX 48.61
- ITOS 35.94
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.